Predictor | Model 1 | | Model 2 | | Model 3 | |
---|
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
Baseline ADAS-Cog | 1.04 (1.01, 1.07) | 0.015* | 1.04 (1.01–1.08) | 0.009* | 1.04 (1.01–1.08) | 0.011* |
Age | | | 1.10 (1.05–1.15) | < 0.001* | 1.10 (1.05–1.16) | < 0.001* |
Gender (Female) | | | 0.61 (0.32–1.18) | 0.143 | 0.63 (0.32–1.24) | 0.178 |
Study Arm | | | 0.82 (0.44–1.54) | 0.534 | 0.70 (0.37–1.36) | 0.294 |
Body Mass Index | | | 1.09 (1.01, 1.16) | 0.023* | 1.10 (1.02, 1.18) | 0.014* |
Education (Years) | | | 1.08 (0.99–1.16) | 0.076 | 1.08 (0.99–1.17) | 0.064 |
Diagnosis Duration | | | 1.07 (0.90–1.26) | 0.443 | 1.07 (0.90–1.26) | 0.466 |
Total Comorbidities | | | | | 0.96 (0.82–1.11) | 0.531 |
Diabetes Mellitus | | | | | 0.41 (0.11–1.59) | 0.195 |
Arthritis | | | | | 0.54 (0.14–2.10) | 0.373 |
Total Medications | | | | | 1.06 (0.94–1.21) | 0.330 |
Benzodiazepine Use | | | | | 1.49 (0.55–4.01) | 0.433 |
Antidepressant Use | | | | | 0.99 (0.49–1.98) | 0.989 |